ANN ARBOR, Mich.--(BUSINESS WIRE)--
Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage
biopharmaceutical company focused on developing and commercializing
first-in-class, oral, low-density lipoprotein cholesterol (LDL-C)
lowering therapies for the treatment of hypercholesterolemia, today
announced the appointment of Gilbert S. Omenn, M.D., Ph.D. as a Class II
Director, with a term of office expiring in 2015 at the annual meeting
of stockholders.
"We are very pleased to welcome Dr. Omenn to the Esperion board of
directors," said Tim Mayleben, president and chief executive officer.
"He has a broad range of scientific, research, and policy experience
within the healthcare industry that will provide valuable insights as we
continue to advance the development of ETC-1002 and expand our product
portfolio."
Dr. Omenn is Professor of Computational Medicine & Bioinformatics,
Internal Medicine, Human Genetics and Public Health, and Director of the
Center for Computational Medicine and Bioinformatics at the University
of Michigan. He serves on the Scientific Management Review Board of the
National Institute of Health (NIH) and the Community Preventive Services
Task Force of the Centers for Disease Control and Prevention (CDC).
Previously, Dr. Omenn served as Chief Executive Officer of the
University of Michigan Health System and Executive Vice President of the
University of Michigan for Medical Affairs. He was Professor of Medicine
and of Environmental Health, and Dean of the School of Public Health and
Community Medicine, at the University of Washington. Dr. Omenn was a
member of the intramural program of NIH in the Anfinsen Lab and was a
Howard Hughes Investigator with NIH grants spanning four decades. He
served previously on the National Cancer Advisory Board, NIH Heart, Lung
and Blood Institute Advisory Council, Society of Fellows for the NIH
National Center for Minority Health and Health Disparities and on the
Director's Advisory Committee for the CDC. Dr. Omenn earned his
Bachelor's degree summa cum laude from Princeton University, his medical
degree magna cum laude from Harvard Medical School, and his Ph.D. in
genetics from the University of Washington. Previously, Dr. Omenn has
been a member of the board of directors for Amgen Inc. and Rohm & Haas
Company.
"As a resident of Ann Arbor with strong ties to the healthcare community
both here in Michigan and around the world, I am eager to join the
Esperion board," said Dr. Omenn. "I believe that ETC-1002 has the
potential to provide statin intolerant patients with a new and much
needed therapeutic alternative to currently available therapies and
those in development."
About Esperion Therapeutics
Esperion Therapeutics, Inc. is a clinical stage biopharmaceutical
company focused on developing and commercializing first-in-class, oral,
LDL-cholesterol lowering therapies for the treatment of patients with
hypercholesterolemia and other cardiometabolic risk markers. ETC-1002,
Esperion's lead product candidate, is a unique, first-in-class, orally
available, once-daily small molecule designed to lower LDL-cholesterol
levels and avoid the side effects associated with therapies currently
available for lowering LDL-cholesterol. ETC-1002 is being developed
primarily for patients intolerant to statins and with elevated levels of
LDL-cholesterol. Phase 2b clinical trials for ETC-1002 are currently
underway and build upon the successful and comprehensive Phase 1 and
Phase 2a programs. For more information, please visit www.esperion.com
and follow us on Twitter at https://twitter.com/EsperionInc.
Forward Looking Statements
This press release contains forward-looking statements that are made
pursuant to the safe harbor provisions of the federal securities laws,
including statements regarding the therapeutic potential of ETC-1002,
the advancement of the ETC-1002 development program, and the expansion
of Esperion's product portfolio. Any statements contained in this press
release that are not statements of historical fact may be deemed to be
forward-looking statements. Forward-looking statements involve risks and
uncertainties that could cause Esperion's actual results to differ
significantly from those projected, including, without limitation, the
risk that unanticipated developments could interfere with the
development (and commercialization) of ETC-1002, as well as other risks
detailed in Esperion's filings with the Securities and Exchange
Commission, including our Annual Report on Form 10-K filed with the
Securities and Exchange Commission on March 13, 2014. You are cautioned
not to place undue reliance on the forward-looking statements, which
speak only as of the date of this release. Esperion disclaims any
obligation or undertaking to update or revise any forward-looking
statements contained in this press release, other than to the extent
required by law.
Media Contact:
W2O Group
Elliot Fox, 212.257.6724
efox@w2ogroup.com
or
Investor
Contact:
Westwicke Partners
Jordan Kohnstam, 443.450.4189
jordan.kohnstam@westwicke.com
Source: Esperion Therapeutics, Inc.
News Provided by Acquire Media